AstraZeneca’s sBLA for LS-SCLC treatment gains FDA priority review
AstraZeneca has received priority review from the US Food and Drug Administration (FDA) for its supplemental Biologics License Application (sBLA) for Imfinzi to treat limited-stage small cell lung cancer (LS-SCLC).
AstraZeneca has received priority review from the US Food and Drug Administration (FDA) for its supplemental Biologics License Application (sBLA) for Imfinzi to treat limited-stage small cell lung cancer (LS-SCLC).
What's Your Reaction?
